Neuro being sold.

Quote






Shire to assess strategic options for its Neuroscience franchise

  • With the acquisition and integration of Baxalta, Shire has solidified its leadership position in rare diseases with an unparalleled inline portfolio, innovative pipeline, and global commercial infrastructure. As part of the Board‘s ongoing commitment to optimize Shire’s portfolio and strategic focus, Shire is assessing strategic options for our Neuroscience franchise to derive even greater value from this franchise. These options may include the independent public listing of the Neuroscience franchise. Shire intends to complete this strategic review by year end.
 






I'm not sure how to read that. (and I think that was on purpose)

Nuero certainly doesn't align with the rare disease model Shire is trying to become. Maybe they carve them off as a subsidiary which is not aligned with shire's overall stock price but still under Shire. Or they sell them.

The main product is in its twilight and despite 2 billion last year, eventually that will go away. The new one coming in Sept cannot begin to cannibalize vyvanse enough to be relevant for 2 or 3 years. Maybe it makes sense to sell the division to a company solely aligned to the disease state.
 






From "The Street";

In addition, the company also said it has launched a strategic review of its neurosciences franchise which could result in an initial public offering. The unit houses its blockbuster Adderall and Vyvanse drugs and had collective sales of $2.6 billion in 2016.
 












Perry is a man of LESS than zero integrity. When I picture him strutting the stage in Dallas talking about how he'd convinced Fleming to keep this division, and how important we are...
Say nothing Perry, instead of lying.

Classless. I hope you have no buyers and a sales force at home doing phone interviews on the day of launch.
 






Once upon a time........

The Neuro Division WAS Shire!
Without it, all these acquisitions & such don't take place..

Shire Richwood is just a plaque on the wall in regards to history of Shire.
 






One interesting question this begs is whether the strategic review might include not only Neuro but other specialty pharma products at Shire. It seems to me that carving out all of the specialty products could make more sense than just spinning off Neuro, while leaving others within the newly focused "rare disease biotech company". I am thinking about Lialda/Pentasa, the other internal medicine products, Xiidra and various pipeline products.
 












This is an admission of failure by FO. He can't make the numbers for Shire work after buying Baxalta without selling off assets, and his "team" couldn't produce the growth needed, nor manage a specialty portfolio. Plus, all R&D could come up with in Neuro was an "old" Shire drug of little obvious value. I love going into orphan when pricing is going to come down and gene therapy companies will take all our share. Great execution by our leaders!
 






I wouldn't exactly call dry eye disease rare, and the pink eye drug will be primary care and pediatric sales force(s). Enter contract sales. NBU should run for the hills, your time is up, and we pay you damn near nothing until you are sold.
 






anonymous said:
This is an admission of failure by FO. He can't make the numbers for Shire work after buying Baxalta without selling off assets, and his "team" couldn't produce the growth needed, nor manage a specialty portfolio. Plus, all R&D could come up with in Neuro was an "old" Shire drug of little obvious value. I love going into orphan when pricing is going to come down and gene therapy companies will take all our share. Great execution by our leaders!
Click to expand...

Baxalta sales soften the blow. Baxalta was the only thing that kept this loss respectable. Baxalta grew, Neuro didn't. Any rational person blames forecasting for Neuro and not the reps, but Baxalta is not the issue in this trainwreck.
 






anonymous said:
Once upon a time........

The Neuro Division WAS Shire!
Without it, all these acquisitions & such don't take place..

Shire Richwood is just a plaque on the wall in regards to history of Shire.
Click to expand...


THIS! He was strutting and stuttering all over that Dallas stage like a snake oil salesman thanking everyone for sticking with him, how he talked Phlegm out of selling us, how Neuro is Shire and the best, blah blah blah.

When not even 5 weeks later we find that they want to get rid of us afterall?

Perry you are a liar and there was zero point to your speech and I am not sure why you would bother. What a mess.
 












"Perry you are a liar and there was zero point to your speech and I am not sure why you would bother. What a mess."


Perry did this same exact thing when he was with Novartis in charge of the Ophthalmic division selling Visudyne. He was up on stage talking about how great the Visudyne division was after they just had a 65% reduction and Lucentis had just launched and made Visudyne irrelevant. Perry went on and on that it was 'our time' and it was growth from here. Believe nothing that comes out of his stuttering and lisping mouth.
 






























Neuro built the company, is the sole reason Flem can play his rare disease games, and is now tossed to the curb? Zero loyalty to their employees, morale as low as it can be, and this spreads to other BUs as they see how "leadership" treats their employees.
 






Top Bottom
Back
Quote